Travis Murdoch, HI-Bio CEO
July 22, 2024 11:32 AM EDT
Deals

HI-Bio dish­es on mo­ti­va­tions for Bio­gen buy­out, cit­ing de­sire to move fast

Max Gelman

Senior Editor

Why did Hu­man Im­munol­o­gy Bio­sciences get bought out less than five months af­ter clos­ing a $95 mil­lion Se­ries B?

HI-Bio’s ex­ec­u­tives were high­ly con­fi­dent in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA de­lays col­orec­tal can­cer de­ci­sion for Am­gen's Lumakras, a set­back in race with Bris­tol My­ers

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times